As of 2024-12-15, the EV/EBITDA ratio of Crinetics Pharmaceuticals Inc (CRNX) is -14.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CRNX's latest enterprise value is 4,659.16 mil USD. CRNX's TTM EBITDA according to its financial statements is -327.75 mil USD. Dividing these 2 quantities gives us the above CRNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 15.1x | 13.8x |
| Forward P/E multiples | 13.4x - 15.3x | 15.0x |
| Fair Price | (43.87) - (49.80) | (47.47) |
| Upside | -181.7% - -192.8% | -188.5% |
| Date | EV/EBITDA |
| 2024-12-13 | -14.22 |
| 2024-12-12 | -14.77 |
| 2024-12-11 | -16.05 |
| 2024-12-10 | -15.21 |
| 2024-12-09 | -15.05 |
| 2024-12-06 | -15.69 |
| 2024-12-05 | -15.36 |
| 2024-12-04 | -15.19 |
| 2024-12-03 | -15.04 |
| 2024-12-02 | -15.27 |
| 2024-11-29 | -15.22 |
| 2024-11-27 | -15.35 |
| 2024-11-26 | -15.10 |
| 2024-11-25 | -14.90 |
| 2024-11-22 | -14.89 |
| 2024-11-21 | -15.17 |
| 2024-11-20 | -14.90 |
| 2024-11-19 | -14.64 |
| 2024-11-18 | -14.23 |
| 2024-11-15 | -14.52 |
| 2024-11-14 | -15.91 |
| 2024-11-13 | -15.70 |
| 2024-11-12 | -15.66 |
| 2024-11-11 | -16.01 |
| 2024-11-08 | -16.20 |
| 2024-11-07 | -15.96 |
| 2024-11-06 | -15.77 |
| 2024-11-05 | -15.39 |
| 2024-11-04 | -15.11 |
| 2024-11-01 | -15.07 |
| 2024-10-31 | -14.87 |
| 2024-10-30 | -14.81 |
| 2024-10-29 | -14.95 |
| 2024-10-28 | -15.20 |
| 2024-10-25 | -15.43 |
| 2024-10-24 | -15.65 |
| 2024-10-23 | -15.56 |
| 2024-10-22 | -15.90 |
| 2024-10-21 | -15.64 |
| 2024-10-18 | -15.75 |
| 2024-10-17 | -15.70 |
| 2024-10-16 | -15.69 |
| 2024-10-15 | -15.33 |
| 2024-10-14 | -14.06 |
| 2024-10-11 | -14.07 |
| 2024-10-10 | -13.68 |
| 2024-10-09 | -13.38 |
| 2024-10-08 | -13.66 |
| 2024-10-07 | -13.68 |
| 2024-10-04 | -14.07 |